Skip to content

A study to evaluate the effects of ROD-001 on choroidal thickness and choroidal blood flow

A study to evaluate the effects of ROD-001 on choroidal thickness and choroidal blood flow

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs032250634
Enrollment
20
Registered
2026-01-09
Start date
2026-01-09
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pre-myopia or myopia

Interventions

Conduct of a game program using SaMD

Sponsors

Matsumura Saiko
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Male or female children aged 5 to 12 years at the time of consent 2) Participants with pre-myopia or myopia through refraction testing under cycloplegia Pre-myopia: Objective equivalent spherical power -0.50 D Myopia: Objective equivalent spherical power -6.00 D 3) Participants with anisometropia within 2.50D. 4) Participants with best corrected visual acuity better than 0 on the logMAR in both eyes 5) Participants deemed eligible by a physician to participate in the eye movement program using ROD-001 6) Written informed consent from participants's guardian or legally acceptable representative have been obtained

Exclusion criteria

Exclusion criteria: 1) Participants with coexisting ocular diseases such as strabismus, amblyopia, or nystagmus 2) Participants with a history of ophthalmic surgery, including eyelid surgery, strabismus surgery, intraocular surgery, or refractive surgery 3) Participants with concomitant ocular diseases involving the cornea, lens, retina, iris, or ciliary body 4) Participants who previously receive treatments for slowing myopia progression within 30 days before Visit2. 5) Participants determined by the investigator to have difficulty in obtaining reliable measurements of choroidal thickness and choroidal blood flow. 6) Participants who have participated in another clinical trial within 3 months before Visit 2 7) Participants who the principal/sub investigator has determined are not suitable to participate in this study

Design outcomes

Primary

MeasureTime frame
Changes in choroidal thickness

Secondary

MeasureTime frame
Changes in choroidal blood flow

Contacts

Public ContactMaiko Hattori

Ark Medical Solutions Inc.

m.hattori@arkms.com+81-70-3267-6309

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026